Home » PRAECIS PHARMA FACES HLDR SUIT OVER CANCER DRUG
PRAECIS PHARMA FACES HLDR SUIT OVER CANCER DRUG
Praecis Pharmaceuticals (PRCS) allegedly failed to disclose material facts regarding its prostate cancer drug, Plenaxis, leading to fiscal-2004 projections that weren't "reasonably founded," according to a purported class-action lawsuit. In a press release, law firm Murray, Frank & Sailer LLP said it filed the lawsuit on behalf of Praecis shareholders between Nov. 25, 2003 and Dec. 6. A representative for drug discovery and development company Praecis wasn't immediately available to comment on the allegations in the lawsuit.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May